Helmut Schaider, MD, associate professor, Dermatology Research Centre, The University of Queensland, Australia, discusses drug resistance in melanoma.<br />
Helmut Schaider, MD, associate professor, Dermatology Research Centre, The University of Queensland, Australia, discusses drug resistance in melanoma.
Adaptive drug resistance occurs in the first 4 to 6 weeks when patients initially start treatment, Schaider explains. Recently, a new model has shown in an in vitro system that if you treat highly proliferative parental cells with a drug, they are slow cycling. The transition from slow-cycling cells to permanently resistant cells has not been looked at in the past.
Recent research has shown that these cells form colonies and start proliferating again. They then form a permanent resistance to the drug to which they were initially exposed.
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More